Apellis Pharmaceuticals Inc

$17.80
(as of Jul 2, 3:58 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Apellis Pharmaceuticals Inc

Stock Price
$17.80
Ticker Symbol
APLS
Exchange
NASDAQ

Industry Information for Apellis Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Apellis Pharmaceuticals Inc

Website
https://apellis.com
Country
USA
Full Time Employees
705

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Fundamentals for Apellis Pharmaceuticals Inc

Market Capitalization
$2,190,637,312
EBITDA
$-184,418,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-1.80
Earnings per Share Estimate Next Year
Profit Margin
-28.83%
Shares Outstanding
125,682,000
Percent Owned by Insiders
13.79%
Percent Owned by Institutions
104.54%
52-Week High
52-Week Low

Technical Indicators for Apellis Pharmaceuticals Inc

50-Day Moving Average
200-Day Moving Average
RSI
46.28
ATR
0.84

Analyst Ratings for Apellis Pharmaceuticals Inc

Strong Buy
10
Buy
4
Hold
8
Sell
0
Strong Sell
0

News About Apellis Pharmaceuticals Inc

Jul 1, 2025, 12:51 PM EST
Investing.com - William Blair has reiterated an Outperform rating on Apellis Pharmaceuticals (NASDAQ:APLS), which has seen its shares decline 46% over the past six months, following the company’s royalty purchase agreement with Sobi. See more.
Jul 1, 2025, 9:04 AM EST
[Close up blood stream concept] See more.
Jul 1, 2025, 7:40 AM EST
STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty obligations to Apellis by 90% for Aspaveli® (systemic pegcetacoplan) in exchange for $275 million upfront and up to $25 million in additional milestone payments dependent on regulatory approvals in the European Union for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). See more.
Jul 1, 2025, 7:00 AM EST
Apellis Pharmaceuticals, Inc. See more.